Chinese PAH Patient Outcomes with Selexipag Triple Therapy, 2022-2023

A retrospective cohort of 153 Chinese patients with pulmonary arterial hypertension (PAH) treated at Qilu Hospital of Shandong University from February 2022 to November 2023. The dataset, authored by Xiaopei Cui, includes safety and efficacy evaluations for patients receiving selexipag-based triple therapy, with a median follow-up of 29 weeks and an average follow-up period of 33 months. It contains non-invasive risk assessments, echocardiogram parameters, and clinical data comparing initial versus early sequential triple combination therapy.

Use Cases

• Compare the efficacy of initial versus sequential triple therapy based on hazard ratios for disease progression events.
• Analyze changes in exercise capacity and right heart structure based on 6-minute walk distance and echocardiogram parameters.
• Model risk stratification improvement based on the count of low-risk criteria before and after treatment.
• Assess the safety profile of selexipag-based triple therapy in a real-world Chinese patient cohort.

Strengths

• Includes 153 patients for safety analysis and 146 for efficacy analysis, providing a defined cohort size.
• Reports specific, statistically significant outcome improvements, such as a hazard ratio of 0.177 for disease progression.
• Contains longitudinal data with a median treatment period of 29 weeks and an average follow-up of 33 months.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may reflect geographic or institutional bias.

Provenance

Source

Qilu Hospital of Shandong University

Collection Method

Single-center, retrospective study.

Time Range

February 2022 to November 2023 (patient presentation), with follow-up data.

Freshness

Last updated 2026-05-21 05:44:05; freshness should be verified.

Geography

China (Shandong province).